Matches in Wikidata for { <http://www.wikidata.org/entity/Q37267506> ?p ?o ?g. }
- Q37267506 description "article científic" @default.
- Q37267506 description "article scientifique" @default.
- Q37267506 description "articolo scientifico" @default.
- Q37267506 description "artigo científico" @default.
- Q37267506 description "artículu científicu espublizáu en 2015" @default.
- Q37267506 description "bilimsel makale" @default.
- Q37267506 description "bài báo khoa học" @default.
- Q37267506 description "scientific article published on 05 March 2015" @default.
- Q37267506 description "vedecký článok" @default.
- Q37267506 description "vetenskaplig artikel" @default.
- Q37267506 description "videnskabelig artikel" @default.
- Q37267506 description "vědecký článek" @default.
- Q37267506 description "wetenschappelijk artikel" @default.
- Q37267506 description "wissenschaftlicher Artikel" @default.
- Q37267506 description "наукова стаття, опублікована в березні 2015" @default.
- Q37267506 description "научни чланак" @default.
- Q37267506 description "مقالة علمية نشرت في 05 مارس 2015" @default.
- Q37267506 name "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 name "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 name "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 type Item @default.
- Q37267506 label "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 label "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 label "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 prefLabel "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 prefLabel "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 prefLabel "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 P1433 Q37267506-1B7FEEF5-6E6B-408E-AEC0-BFA038A39571 @default.
- Q37267506 P1476 Q37267506-85053067-353E-4BC1-8B57-2D35A465C511 @default.
- Q37267506 P2093 Q37267506-3074AA5C-4410-4F9C-8BDE-089D2CC3478E @default.
- Q37267506 P2093 Q37267506-3AE32078-9B72-4E95-A469-92498CF4C604 @default.
- Q37267506 P2093 Q37267506-9915EF1F-40F3-454D-9E0F-2E6AD2C97A15 @default.
- Q37267506 P2093 Q37267506-A6B57446-3981-4C84-A408-3CA6D62C2B62 @default.
- Q37267506 P2093 Q37267506-B0143CD8-8C96-48E2-B03C-41646CA78E78 @default.
- Q37267506 P2093 Q37267506-D39B4026-EA7D-4DF6-8A30-F97467BFA9F5 @default.
- Q37267506 P2093 Q37267506-D679A1A3-E27B-4D78-AF84-ECCD4C95E168 @default.
- Q37267506 P2860 Q37267506-0B5C3A79-42CC-4135-A7CA-053E9AAC596C @default.
- Q37267506 P2860 Q37267506-0DBDB3AF-D672-4C9F-AD67-1A0ECF5F6259 @default.
- Q37267506 P2860 Q37267506-0F03A52C-6122-4618-8725-A2FFAA50B1AD @default.
- Q37267506 P2860 Q37267506-13754C51-28AB-4C59-A72E-7CBC8811130A @default.
- Q37267506 P2860 Q37267506-15DAB3ED-FFAB-455C-85BE-576C2D5960FE @default.
- Q37267506 P2860 Q37267506-1959E77B-C686-488B-86D2-008100733BB2 @default.
- Q37267506 P2860 Q37267506-1B044B0B-5DBA-4753-BFEE-984310CF1424 @default.
- Q37267506 P2860 Q37267506-1FA1BA4D-E9AF-4DA9-8C77-79B9631C799C @default.
- Q37267506 P2860 Q37267506-1FAAAC88-32A4-444E-8905-A32C46B92B2C @default.
- Q37267506 P2860 Q37267506-2563EAAE-E8B9-4371-8300-BBC767C75F9B @default.
- Q37267506 P2860 Q37267506-2C24083D-E0B8-4142-814F-389789936459 @default.
- Q37267506 P2860 Q37267506-2E7CCBD5-F77F-4E02-AC18-5B09579363BE @default.
- Q37267506 P2860 Q37267506-300D765B-EBEC-4C19-B116-4D861DB4112D @default.
- Q37267506 P2860 Q37267506-356231DD-393F-4768-920E-72DC3552E93E @default.
- Q37267506 P2860 Q37267506-35DFCDE9-8395-4A81-9C51-62CB9842EF45 @default.
- Q37267506 P2860 Q37267506-38733F0C-8512-4C15-B683-BFC8FEEEEF93 @default.
- Q37267506 P2860 Q37267506-4C0F3A62-BBB0-49CA-B3B5-C903EAE8ADC7 @default.
- Q37267506 P2860 Q37267506-50C1B1D2-7DAC-44E6-8493-2235734F1145 @default.
- Q37267506 P2860 Q37267506-68FE004F-A371-4856-AD06-765ECAFB7999 @default.
- Q37267506 P2860 Q37267506-7B439220-E1F6-444C-BB95-9BA3625E32D6 @default.
- Q37267506 P2860 Q37267506-8620E0BF-E78B-4ED0-B106-C609AD8C649E @default.
- Q37267506 P2860 Q37267506-8D9DB92F-F85C-4AB8-BB04-9312090C5A58 @default.
- Q37267506 P2860 Q37267506-911997F0-4CF0-433D-89B5-07FEB6D5A897 @default.
- Q37267506 P2860 Q37267506-92B1B46D-8303-49F0-A6E2-4C5C2DE8CCC2 @default.
- Q37267506 P2860 Q37267506-999A5554-CFD9-40C3-B6AE-F3088063C128 @default.
- Q37267506 P2860 Q37267506-AB76F623-ED5C-4D23-9AF4-94B326C56F59 @default.
- Q37267506 P2860 Q37267506-AD1455DE-F9D3-4086-A435-AADF84646C2C @default.
- Q37267506 P2860 Q37267506-AE904F4E-C945-4739-B078-D3F7ADADD4C5 @default.
- Q37267506 P2860 Q37267506-B2A690B5-7CA4-40C9-B1D4-BD71FBB2F01D @default.
- Q37267506 P2860 Q37267506-B385B4C7-CFCC-4926-AAEE-D51D9D872A73 @default.
- Q37267506 P2860 Q37267506-B5B22263-5234-47EB-8587-9E97A258E144 @default.
- Q37267506 P2860 Q37267506-C4AAA938-5C39-4626-8A01-F97FB0F02421 @default.
- Q37267506 P2860 Q37267506-C4DAC762-4BF1-4F15-B01E-EF6310F89ECE @default.
- Q37267506 P2860 Q37267506-CAC46DE8-A25D-4BE3-B700-A013DE580F8A @default.
- Q37267506 P2860 Q37267506-DC56F76F-107B-43E5-B895-EC0F2D0A5B1E @default.
- Q37267506 P2860 Q37267506-E2439F23-CC58-40A7-B855-E20CBAFC4D36 @default.
- Q37267506 P2860 Q37267506-E2F2B869-0502-4C09-9737-2D8486F782F2 @default.
- Q37267506 P2860 Q37267506-EBD47D97-7839-4CDD-A4DB-73C4C66B1B16 @default.
- Q37267506 P304 Q37267506-639F98B9-4FF5-4EDB-8EF8-BA542B7DB03F @default.
- Q37267506 P31 Q37267506-2804B244-1D48-4136-ADB9-8551F0AD28A2 @default.
- Q37267506 P356 Q37267506-C332CD61-05AF-4C49-B2FD-B0E0AD9531EC @default.
- Q37267506 P407 Q37267506-BFF98E11-9268-40D6-ACA0-0DFC476A8B07 @default.
- Q37267506 P433 Q37267506-4A577A20-3828-4EAA-A7F4-8877CC72FA13 @default.
- Q37267506 P478 Q37267506-D327579D-A5AC-4052-9F7B-30DF35E2101B @default.
- Q37267506 P50 Q37267506-17B6D790-19F7-45BE-823B-8DC4CD796B57 @default.
- Q37267506 P50 Q37267506-1D412069-3550-4F99-8686-7350E8C1989A @default.
- Q37267506 P50 Q37267506-AB24A820-C7F1-47D1-B611-16904336D20A @default.
- Q37267506 P577 Q37267506-5910C828-6A99-4F78-A01B-FFF6E0F012E6 @default.
- Q37267506 P698 Q37267506-244227B0-49D6-415F-A387-A08DA32A18BD @default.
- Q37267506 P8608 Q37267506-8DADD779-E303-44DC-A0FA-7D1255E935AE @default.
- Q37267506 P921 Q37267506-46F55C09-A909-4E3E-966D-0C479D1B814D @default.
- Q37267506 P921 Q37267506-8DDD7408-2F32-4AE9-AC64-3B8B2DC6F52D @default.
- Q37267506 P921 Q37267506-FF8C9745-0EEC-498E-B3ED-A206B66C82B9 @default.
- Q37267506 P932 Q37267506-D8036D85-9A4D-49A0-BC41-4A25852E991B @default.
- Q37267506 P356 J.CLML.2015.02.020 @default.
- Q37267506 P698 25842225 @default.
- Q37267506 P1433 Q5133774 @default.
- Q37267506 P1476 "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study" @default.
- Q37267506 P2093 "Claudio Zanna" @default.
- Q37267506 P2093 "Elisabeth Rouits" @default.
- Q37267506 P2093 "Gregoire Vuagniaux" @default.
- Q37267506 P2093 "Harry P Erba" @default.
- Q37267506 P2093 "J Mel Sorensen" @default.
- Q37267506 P2093 "Jeffrey M Brill" @default.